| Agent |
Company |
Indication |
Targets |
References |
| Sorafenib |
Onyx/Bayer |
RCC, HCC |
VEGFR, PDGFR, c-Kit, Raf |
[38-41] |
| Nilotinib |
Novartis |
CML |
Bcr-Abl, PDGFR, cSrc, c-Kit |
[42] |
| Sunitinib |
Pfizer |
GIST, RCC |
PDGFR, VEGFR, c-Kit, RET, FLT3 |
[43] |
| Crizotinib |
Pfizer |
NSCLC |
EML4/ALK, HGFR |
[44, 45,223] |
| Motesanib |
Amgen/Takeda |
Breast cancer |
PDGFR, VEGFR, c-Kit |
[46] |
| Vandetanib |
Astra Zeneca |
Thyroid, NSCLC |
EGFR, VEGFR, RET |
[30] |
| Lesaurtinib |
Cephalon |
AML |
JAK2, FLT3, Trk |
[48,49] |
| Cabozatinib |
Exelixis |
Thyroid, solid tumors |
VEGFR, MET, c-Kit, FLT3, RET, TEK |
[51,52] |
| Pazopanib |
GlaxoSmithKline |
RCC, sarcoma |
VEGFR, PDGFR, c-Kit |
[53] |
Abbreviations: RCC: Renal cell carcinoma; HCC: Hepato cellular carcinoma; CML: Chronic myelogenousleukemia; GIST: Gastro-intestinal stromal tumor; NSCLC: Nonsmall-
cell Lung cancer; AML: Angiomyolipoma; VEGFR: Vascular endothelial growth factor receptor; PDGFR: Platelet-derived growth factor receptor; cKit: Mast/stem cell
growth factor receptor; cSrc: tyrosine-protein kinase; Bcr-Abl: Break cluster region-Abelson leukemia; RET: REarranged during transfection; FLT3: FMS-like tyrosine kinase
3; EML4: Echinoderm microtubule-associated protein-like 4; ALK: Anaplastic lymphoma kinase; HGFR: Hepatocyte growth factor receptor; JAK2: Janus kinase 2; Trk:
Tropomyosinreceptorkinase; TEK: Tyrosine kinase, endothelial. |
